Imextor SR 500 Tablet

This results in improved glycemic control without significant risk of hypoglycemia. Imextor SR 500 is formulated as a sustained-release tablet to provide stable plasma concentrations, allowing once or twice-daily dosing for optimal therapeutic effect and patient compliance. Clinical studies have demonstrated that Imeglimin effectively reduces HbA1c levels, fasting plasma glucose, and postprandial glucose excursions when used as monotherapy or in combination with other antidiabetic agents such as metformin or SGLT2 inhibitors.

The safety profile of Imextor SR 500 is favorable, with the most common adverse effects being mild gastrointestinal disturbances. It is contraindicated in patients with severe renal impairment or hypersensitivity to the active substance. Regular monitoring of glycemic parameters and renal function is recommended during therapy. Imextor SR 500 offers a promising option for comprehensive glycemic management in type 2 diabetes patients.